Diabetic Retinopathy Market Growth Analysis By DelveInsight
DelveInsight's "Diabetic Retinopathy Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the disease, historical and forecasted epidemiology, the pipeline insight as well as the Diabetic Retinopathy market size and shares analysis in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. The report also covers emerging drugs, current treatment practices, Diabetic Retinopathy market shares of the individual therapies, a detailed current Diabetic Retinopathy treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the market.
Diabetic retinopathy (DR) is a common and specific microvascular complication of diabetes and remains the leading cause of preventable blindness in working-ged people. It is identified in a third of people with diabetes and is associated with an increased risk of life-threatening systemic vascular complications, including stroke, coronary heart disease, and heart failure. In the USA, an estimated 40% (8% for vision-threatening retinopathy) of people with type 2 diabetes and 86% (42%) with type 1 diabetes have diabetic retinopathy.
Diabetic Retinopathy Market Key Facts
- The total diagnosed prevalent population of Diabetic Retinopathy (DR) in the 7MM countries was estimated to be 8,033,083 cases in 2020.
- According to DelveInsight’s estimates, among the number of patients diagnosed with DR among 7MM countries, the US accounts for the highest population. The US accounted for the highest diagnosed prevalence and the cases were 4,372,304 in 2020.
- Among the European countries, Germany had the highest population of Diabetic Retinopathy with 2,167,200 cases, followed by Italy which had 1,485,668 cases in 2020. While France had the lowest prevalent population with 575,507 cases in 2020.
- The prevalent population of Diabetic Retinopathy in Japan was 1,903,502 cases, in 2020.
- Age is an important factor in the progression of the disease. In 2020, there were 1,632,516 cases in the age group of 50 to 64 years which was the highest in any age group.
Diabetic Retinopathy Market Analysis
The Diabetic Retinopathy Market Size is anticipated to increase during the study period owing to the greater understanding of DR, growing awareness, improved management, increased prevalence, and the expected launch of novel therapies by key players such as Roche, Novartis Pharmaceuticals during the forecast period.
The Diabetic Retinopathy market analysis section of the report helps to understand the current and forecasted Diabetic Retinopathy market trends and growth by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers. The report gives complete detail of Diabetic Retinopathy Market Size and Shares of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Diabetic Retinopathy Epidemiology Forecast
The Diabetic Retinopathy epidemiology section covers insights about historical and current Diabetic Retinopathy patient pool and forecasted trends for every seven major countries (i.e., the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan. It helps to recognize the causes of current and forecasted Diabetic Retinopathy Epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends, along with assumptions undertaken.
Diabetic Retinopathy Epidemiology Segmentation
- Total Prevalent cases of Diabetic Retinopathy
- Gender-specific cases of Diabetic Retinopathy
- Age-specific causes of Diabetic Retinopathy
Diabetic Retinopathy Therapeutics Pipeline
Several unmet needs of the patients dealing with Diabetic Retinopathy need to be addressed. It is essential that to provide holistic care to patients, novel diagnostic tools, novel pathways that address the underlying cause of the disease and timely diagnosis need to be developed. At present to address these unmet needs companies worldwide are diligently involved in the therapeutic development for Diabetic Retinopathy.
Some of the key companies in the Diabetic Retinopathy Market includes Roche, Kubota Vision, Novartis, Pharmaceuticals, Adverum Biotechnologies, KalVista Pharmaceuticals, and others. Diabetic Retinopathy Therapies covered in the report include KVD001, Brolucizumabt, Faricimab, ADVM-022, Emixustat Hydrochloride, and many more. '
For more details, visit: Diabetic Retinopathy Market Growth